Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer-Reference-Cited by-同舟云学术

Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer

Published:2022-12 Issue: Volume:174 Page:146-156
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Mazieres Julien,Iadeluca Laura,Shaw Alice T.,Solomon Benjamin J.,Bauer Todd M.,de Marinis Filippo,Felip Enriqueta,Goto Yasushi,Kim Dong-Wan,Mok Tony,Reisman Arlene,Thurm Holger,Polli Anna M.,Liu Geoffrey

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference38 articles.

1. Quality of life of patients with lung cancer;Polanski;Onco Targets Ther.,2016

2. Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: Results from a prospective medical record registry study;Walker;Health Quality Life Outcomes.,2017

3. Brain metastases in patients with ALK+ non-small cell lung cancer: Clinical symptoms, treatment patterns and economic burden;Guérin;J. Med. Econ.,2015

4. Treatment of brain metastases of non-small cell lung carcinoma;Rybarczyk-Kasiuchnicz;Int. J. Mol. Sci.,2021

5. Effect of brain metastasis on patient-reported outcomes in advanced NSCLC treated in real-world community oncology settings;Walker;Clin. Lung Cancer.,2018

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurocognitive Adverse Events Related to Lorlatinib in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis;Cancers;2024-07-22

2. Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials;Cancers;2024-07-04

3. Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer;The Lancet Regional Health - Western Pacific;2024-07

4. A pragmatic guide for management of adverse events associated with lorlatinib;Lung Cancer;2024-05

5. Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis;BMC Cancer;2024-02-08